HGH 191AA (10IU Vial)
HGH 191AA is recombinant human growth hormone (somatropin) identical to endogenous GH, studied extensively for its effects on body composition, metabolism, and tissue repair. Clinical protocols typically employ subcutaneous administration once daily to mimic physiological GH secretion patterns. This educational protocol presents a gradual titration approach using practical dilution for precise insulin-syringe measurements.
Detailed protocol below.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 200 mcg | 18 units (0.18 mL) |
| Week 2 | 300 mcg | 27 units (0.27 mL) |
| Week 3 | 400 mcg | 36 units (0.36 mL) |
| Week 4 | 500 mcg | 45 units (0.45 mL) |
| Week 5 | 600 mcg | 54 units (0.54 mL) |
| Week 6 | 700 mcg | 63 units (0.63 mL) |
| Week 7 | 800 mcg | 72 units (0.72 mL) |
| Week 8 | 900 mcg | 81 units (0.81 mL) |
- •Peptide Vials (HGH 191AA, 10 IU / 3.33 mg each):
- •Insulin Syringes (U-100):
- •Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Pfizer (Genotropin) Prescribing Information
Adult GH deficiency dosing: recommended start 0.45–0.90 IU (0.15–0.30 mg) SC daily; maintenance dose seldom exceeds 4 IU (≈1.33 mg) daily
View sourceEMD Serono (Serostim) Prescribing Information
HIV-associated wasting dose: 0.1 mg/kg SC daily (up to ~6 mg/day); administer injections subcutaneously, preferably at bedtime
View sourceMedsafe NZ Data Sheet (Omnitrope)
Subcutaneous injection technique: site rotation to prevent lipoatrophy; recommends 0.15–0.30 mg per day to start in adults, titrating up to ~1.3 mg/day as needed
View sourceHadzovic et al., Bosn. J. Basic Med. Sci. 2004
GH usage and abuse review: moderate doses of GH (70–400 mcg in healthy adults) produce dose-dependent increases in lipolysis and fat oxidation
View sourceSaizen® (somatropin) FDA Label
Lyophilized 191aa HGH is a sterile, white powder for SC or IM injection after reconstitution with bacteriostatic water; potency: 5 mg ≈ 15 IU and 8.8 mg ≈ 26.4 IU
View sourceSuperior Peptide (Product Data)
HGH 191AA is provided as a lyophilized powder intended for subcutaneous (or intramuscular) injection after reconstitution with bacteriostatic water
View sourceRudman et al., N. Engl. J. Med. 1990
Pivotal study in older men: six months of HGH (0.03 mg/kg 3× weekly) significantly increased lean body mass and decreased adipose mass compared to placebo
View sourceGötherström et al., J. Clin. Endocrinol. Metab. 2010
10-year adult GH deficiency follow-up: initial ~0.72 mg/day GH replacement (then reduced to ~0.37 mg/day long-term) led to sustained increases in muscle strength and improved body composition
View sourceSathiavageeswaran et al., Clin. Endocrinol. 2007
Trial in 60–77 y/o adults: low-dose GH (~0.16 mg/day for 12 months) was administered to evaluate cognitive effects, illustrating a conservative dosing regimen
View sourceLiu et al., Ann. Intern. Med. 2008
Systematic review of GH in healthy athletes: GH administration increased lean body mass but did not significantly improve muscle strength or exercise performance
View sourceCDC Vaccine Administration Guidelines
Subcutaneous injection technique: angle/site selection; no aspiration required for subcutaneous route
View sourceCDC Subcutaneous Injection Technique (PDF)
Technique diagram and site guidance for subcutaneous injections
View sourceNCBI Bookshelf
Best practices for injection: asepsis, preparation, and administration techniques
View source
Educational content adapted from peptidedosages.com. Not medical advice.